These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19639273)

  • 1. Human invariant natural killer T cells: implications for immunotherapy.
    Takahashi T; Kurokawa M
    Int J Hematol; 2009 Sep; 90(2):137-142. PubMed ID: 19639273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications.
    Papoutselis M; Spanoudakis E
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):358-365. PubMed ID: 32234294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.
    Terabe M; Berzofsky JA
    Cancer Immunol Immunother; 2014 Mar; 63(3):199-213. PubMed ID: 24384834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulatory role of invariant NKT cells in tumor immunity.
    McEwen-Smith RM; Salio M; Cerundolo V
    Cancer Immunol Res; 2015 May; 3(5):425-35. PubMed ID: 25941354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
    Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
    Front Immunol; 2018; 9():1266. PubMed ID: 29928278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
    Wolf BJ; Choi JE; Exley MA
    Front Immunol; 2018; 9():384. PubMed ID: 29559971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of NKT cells in cancer immunotherapy.
    Bae EA; Seo H; Kim IK; Jeon I; Kang CY
    Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.
    Yang G; Artiaga BL; Lewis ST; Driver JP
    Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
    Webb TJ; Bieler JG; Schneck JP; Oelke M
    J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invariant natural killer T cells in immune surveillance and tumor immunotherapy: perspectives and potentials.
    Haeryfar SM
    Arch Iran Med; 2008 Mar; 11(2):186-95. PubMed ID: 18298297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms.
    Bagnara D; Ibatici A; Corselli M; Sessarego N; Tenca C; De Santanna A; Mazzarello A; Daga A; Corvò R; De Rossi G; Frassoni F; Ciccone E; Fais F
    Haematologica; 2009 Jul; 94(7):967-74. PubMed ID: 19454494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
    Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
    Front Immunol; 2018; 9():1990. PubMed ID: 30298063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic strategies targeting natural killer T cell responses in cancer.
    Shissler SC; Bollino DR; Tiper IV; Bates JP; Derakhshandeh R; Webb TJ
    Immunogenetics; 2016 Aug; 68(8):623-38. PubMed ID: 27393665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity.
    de Araújo ND; Gama FM; de Souza Barros M; Ribeiro TLP; Alves FS; Xabregas LA; Tarragô AM; Malheiro A; Costa AG
    J Immunol Res; 2021; 2021():6633824. PubMed ID: 33506055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
    Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions.
    Singh AK; Gaur P; Das SN
    Hum Immunol; 2014 Mar; 75(3):250-60. PubMed ID: 24373798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor Responses of Invariant Natural Killer T Cells.
    Altman JB; Benavides AD; Das R; Bassiri H
    J Immunol Res; 2015; 2015():652875. PubMed ID: 26543874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote
    Jahnke S; Schmid H; Secker KA; Einhaus J; Duerr-Stoerzer S; Keppeler H; Schober-Melms I; Baur R; Schumm M; Handgretinger R; Bethge W; Kanz L; Schneidawind C; Schneidawind D
    Front Immunol; 2019; 10():1542. PubMed ID: 31354710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of invariant NKT cells at the interface of innate and adaptive immunity.
    Cerundolo V; Kronenberg M
    Semin Immunol; 2010 Apr; 22(2):59-60. PubMed ID: 20172739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.